Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia.

Ooi CJ, Hilmi I, Banerjee R, Chuah SW, Ng SC, Wei SC, Makharia GK, Pisespongsa P, Chen MH, Ran ZH, Ye BD, Park DI, Ling KL, Ong D, Ahuja V, Goh KL, Sollano J, Lim WC, Leung WK, Ali RAR, Wu DC, Ong E, Mustaffa N, Limsrivilai J, Hisamatsu T, Yang SK, Ouyang Q, Geary R, De Silva JH, Rerknimitr R, Simadibrata M, Abdullah M, Leong RW; Asia Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease and Asian Organization for Crohn’s and Colitis.

Intest Res. 2019 May 31. doi: 10.5217/ir.2019.00026. [Epub ahead of print] Review.

2.

Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia.

Ooi CJ, Hilmi I, Banerjee R, Chuah SW, Ng SC, Wei SC, Makharia GK, Pisespongsa P, Chen MH, Ran ZH, Ye BD, Park DI, Ling KL, Ong D, Ahuja V, Goh KL, Sollano J, Lim WC, Leung WK, Ali RAR, Wu DC, Ong E, Mustaffa N, Limsrivilai J, Hisamatsu T, Yang SK, Ouyang Q, Geary R, De Silva JH, Rerknimitr R, Simadibrata M, Abdullah M, Leong RWL; Asia-Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease and Asian Organization for Crohn's and Colitis.

J Gastroenterol Hepatol. 2019 Mar 8. doi: 10.1111/jgh.14648. [Epub ahead of print] Review.

PMID:
30848854
3.

Asia-Pacific consensus statements on Crohn's disease. Part 2: Management.

Ooi CJ, Makharia GK, Hilmi I, Gibson PR, Fock KM, Ahuja V, Ling KL, Lim WC, Thia KT, Wei SC, Leung WK, Koh PK, Gearry RB, Goh KL, Ouyang Q, Sollano J, Manatsathit S, de Silva HJ, Rerknimitr R, Pisespongsa P, Abu Hassan MR, Sung J, Hibi T, Boey CC, Moran N, Leong RW; Asia Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease.

J Gastroenterol Hepatol. 2016 Jan;31(1):56-68. doi: 10.1111/jgh.12958. Review.

PMID:
25819311
4.

Asia Pacific Consensus Statements on Crohn's disease. Part 1: Definition, diagnosis, and epidemiology: (Asia Pacific Crohn's Disease Consensus--Part 1).

Ooi CJ, Makharia GK, Hilmi I, Gibson PR, Fock KM, Ahuja V, Ling KL, Lim WC, Thia KT, Wei SC, Leung WK, Koh PK, Gearry RB, Goh KL, Ouyang Q, Sollano J, Manatsathit S, de Silva HJ, Rerknimitr R, Pisespongsa P, Abu Hassan MR, Sung J, Hibi T, Boey CC, Moran N, Leong RW; Asia Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease.

J Gastroenterol Hepatol. 2016 Jan;31(1):45-55. doi: 10.1111/jgh.12956. Review.

PMID:
25819140
5.

Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: Management.

Park DI, Hisamatsu T, Chen M, Ng SC, Ooi CJ, Wei SC, Banerjee R, Hilmi IN, Jeen YT, Han DS, Kim HJ, Ran Z, Wu K, Qian J, Hu PJ, Matsuoka K, Andoh A, Suzuki Y, Sugano K, Watanabe M, Hibi T, Puri AS, Yang SK.

J Gastroenterol Hepatol. 2018 Jan;33(1):30-36. doi: 10.1111/jgh.14018. Review.

PMID:
29024102
6.

Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.

Chatzinasiou F, Polymeros D, Panagiotou M, Theodoropoulos K, Rigopoulos D.

Acta Dermatovenerol Croat. 2016 Apr;24(1):83-5.

PMID:
27149138
7.

Asian Organization for Crohn's and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: Risk assessment.

Park DI, Hisamatsu T, Chen M, Ng SC, Ooi CJ, Wei SC, Banerjee R, Hilmi IN, Jeen YT, Han DS, Kim HJ, Ran Z, Wu K, Qian J, Hu PJ, Matsuoka K, Andoh A, Suzuki Y, Sugano K, Watanabe M, Hibi T, Puri AS, Yang SK.

J Gastroenterol Hepatol. 2018 Jan;33(1):20-29. doi: 10.1111/jgh.14019. Review.

PMID:
29023903
8.

Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.

Magro F, Portela F.

BioDrugs. 2010 Dec 14;24 Suppl 1:3-14. doi: 10.2165/11586290-000000000-00000. Review.

PMID:
21175228
9.

European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal ['Exit Strategies'] in Inflammatory Bowel Disease.

Doherty G, Katsanos KH, Burisch J, Allez M, Papamichael K, Stallmach A, Mao R, Berset IP, Gisbert JP, Sebastian S, Kierkus J, Lopetuso L, Szymanska E, Louis E.

J Crohns Colitis. 2018 Jan 5;12(1):17-31. doi: 10.1093/ecco-jcc/jjx101. Review.

10.

Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America.

North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition; Colitis Foundation of America, Bousvaros A, Antonioli DA, Colletti RB, Dubinsky MC, Glickman JN, Gold BD, Griffiths AM, Jevon GP, Higuchi LM, Hyams JS, Kirschner BS, Kugathasan S, Baldassano RN, Russo PA.

J Pediatr Gastroenterol Nutr. 2007 May;44(5):653-74.

PMID:
17460505
11.

The Asia-Pacific consensus on ulcerative colitis.

Ooi CJ, Fock KM, Makharia GK, Goh KL, Ling KL, Hilmi I, Lim WC, Kelvin T, Gibson PR, Gearry RB, Ouyang Q, Sollano J, Manatsathit S, Rerknimitr R, Wei SC, Leung WK, de Silva HJ, Leong RW; Asia Pacific Association of Gastroenterology Working Group on Inflammatory Bowel Disease.

J Gastroenterol Hepatol. 2010 Mar;25(3):453-68. doi: 10.1111/j.1440-1746.2010.06241.x. Review.

PMID:
20370724
12.

Incidence of Crohn's Disease and Ulcerative Colitis in Rhode Island: Report from the Ocean State Crohn's and Colitis Area Registry.

Shapiro JM, Zoega H, Shah SA, Bright RM, Mallette M, Moniz H, Grabert SA, Bancroft B, Merrick M, Flowers NT, Samad Z, Lidofsky S, LeLeiko NS, Sands BE.

Inflamm Bowel Dis. 2016 Jun;22(6):1456-61. doi: 10.1097/MIB.0000000000000745.

13.

Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn's and colitis epidemiology study.

Ng SC, Tang W, Ching JY, Wong M, Chow CM, Hui AJ, Wong TC, Leung VK, Tsang SW, Yu HH, Li MF, Ng KK, Kamm MA, Studd C, Bell S, Leong R, de Silva HJ, Kasturiratne A, Mufeena MNF, Ling KL, Ooi CJ, Tan PS, Ong D, Goh KL, Hilmi I, Pisespongsa P, Manatsathit S, Rerknimitr R, Aniwan S, Wang YF, Ouyang Q, Zeng Z, Zhu Z, Chen MH, Hu PJ, Wu K, Wang X, Simadibrata M, Abdullah M, Wu JC, Sung JJY, Chan FKL; Asia–Pacific Crohn's and Colitis Epidemiologic Study (ACCESS) Study Group.

Gastroenterology. 2013 Jul;145(1):158-165.e2. doi: 10.1053/j.gastro.2013.04.007. Epub 2013 Apr 9.

PMID:
23583432
14.

Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management.

Park DI, Hisamatsu T, Chen M, Ng SC, Ooi CJ, Wei SC, Banerjee R, Hilmi IN, Jeen YT, Han DS, Kim HJ, Ran Z, Wu K, Qian J, Hu PJ, Matsuoka K, Andoh A, Suzuki Y, Sugano K, Watanabe M, Hibi T, Puri AS, Yang SK.

Intest Res. 2018 Jan;16(1):17-25. doi: 10.5217/ir.2018.16.1.17. Epub 2018 Jan 18. Review.

15.

TNFα-Inhibitors in Inflammatory Bowel Disease [Internet].

Ringerike T, Elvsaas IKØ, Coll P, Lundin KEA, Movik E, Gjertsen MK.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2008 Dec.

16.

Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment.

Park DI, Hisamatsu T, Chen M, Ng SC, Ooi CJ, Wei SC, Banerjee R, Hilmi IN, Jeen YT, Han DS, Kim HJ, Ran Z, Wu K, Qian J, Hu PJ, Matsuoka K, Andoh A, Suzuki Y, Sugano K, Watanabe M, Hibi T, Puri AS, Yang SK.

Intest Res. 2018 Jan;16(1):4-16. doi: 10.5217/ir.2018.16.1.4. Epub 2018 Jan 18. Review.

17.

Treatment of inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 2(nd) Asian Organization of Crohn's and Colitis (AOCC) meeting in Seoul.

Nakase H, Keum B, Ye BD, Park SJ, Koo HS, Eun CS.

Intest Res. 2016 Jul;14(3):231-9. doi: 10.5217/ir.2016.14.3.231. Epub 2016 Jun 27. Erratum in: Intest Res. 2016 Oct;14 (4):381.

18.
19.

Proteolytic cleavage and loss of function of biologic agents that neutralize tumor necrosis factor in the mucosa of patients with inflammatory bowel disease.

Biancheri P, Brezski RJ, Di Sabatino A, Greenplate AR, Soring KL, Corazza GR, Kok KB, Rovedatti L, Vossenkämper A, Ahmad N, Snoek SA, Vermeire S, Rutgeerts P, Jordan RE, MacDonald TT.

Gastroenterology. 2015 Nov;149(6):1564-1574.e3. doi: 10.1053/j.gastro.2015.07.002. Epub 2015 Jul 11.

20.

Advances in biologic therapy for ulcerative colitis and Crohn's disease.

D'Haens G, Daperno M.

Curr Gastroenterol Rep. 2006 Dec;8(6):506-12. Review.

PMID:
17105690

Supplemental Content

Support Center